# Fiona Blackhall

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/fiona-blackhall/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,893 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 91 |
| i10-index | 281 |
| Last Known Institution | University of Manchester |
| OpenAlex ID | https://openalex.org/A5089954905 |
| ORCID iD | https://orcid.org/0000-0001-8716-3395 |
| Works | 668 |

## Researcher papers

- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer](https://scholariq.org/papers/first-line-crizotinib-versus-chemotherapy-in-i-alk-i-positive-lung-cancer/)
- [Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component](https://scholariq.org/papers/osimertinib-in-pretreated-t790m-positive-advanced-non-small-cell-lung-cancer/)
- [Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer](https://scholariq.org/papers/tarlatamab-for-patients-with-previously-treated-small-cell-lung-cancer/)
- [The evolution of lung cancer and impact of subclonal selection in TRACERx](https://scholariq.org/papers/the-evolution-of-lung-cancer-and-impact-of-subclonal-selection-in-tracerx/)
- [Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/randomized-phase-ii-study-of-dacomitinib-pf-00299804-an-irreversible-pan-human/)
- [The evolution of non-small cell lung cancer metastases in TRACERx](https://scholariq.org/papers/the-evolution-of-non-small-cell-lung-cancer-metastases-in-tracerx/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)

## Researcher university

- [University of Manchester](https://scholariq.org/institutions/university-of-manchester/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.